Literature DB >> 11742490

IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai.

N M Probst-Hensch1, J M Yuan, F Z Stanczyk, Y T Gao, R K Ross, M C Yu.   

Abstract

This is the first study to investigate the associations of IGF-1, IGF-2 and IGFBP-3 concentrations with the risk of colorectal cancer in prospectively collected blood samples from an Oriental population. Between 1986 and 1989 serum samples were collected at baseline from 18 244 men, aged 45-65 years, without a history of cancer and living in Shanghai, China. IGF-1, IGF-2 and IGFBP-3 were measured in the serum of 135 men who developed colorectal cancer over 12 years of follow-up and 661 control subjects drawn from the cohort, who were matched to the index cases by neighbourhood of residence, age, and year and month of sample collection. Serum IGF-1 was not associated with risk of colorectal cancer. IGF-2 and IGFBP-3, on the other hand, exhibited statistically significant, positive associations with colorectal cancer risk when cases were confined to those diagnosed within a relatively short time period after enrollment (within 8 years). After adjustment for body mass index, cigarette smoking and alcohol intake, men in the highest versus the lowest quintile of IGF-2 and IGFBP-3 showed odds ratios of 2.74 (95% Cl = 1.67-4.50; 2-sided P for trend = 0.0008) and 2.85 (95% Cl = 1.69-4.81; 2-sided P for trend = 0.01), respectively. Our data thus suggest that circulating IGF-2 and IGFBP-3 can serve as early indicators of impending colorectal cancer. (c) 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742490      PMCID: PMC2363974          DOI: 10.1054/bjoc.2001.2172

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  Insulin-like growth factor-I and binding protein-3 and risk of cancer.

Authors:  E Giovannucci
Journal:  Horm Res       Date:  1999

2.  Circulating insulin-like growth factor II and colorectal adenomas.

Authors:  A G Renehan; J E Painter; D O'Halloran; W S Atkin; C S Potten; S T O'Dwyer; S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

Review 3.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

4.  IGF-I and IGF-II in relation to colorectal cancer.

Authors:  O Manousos; J Souglakos; C Bosetti; A Tzonou; V Chatzidakis; D Trichopoulos; H O Adami; C Mantzoros
Journal:  Int J Cancer       Date:  1999-09-24       Impact factor: 7.396

5.  A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.

Authors:  E Giovannucci; M N Pollak; E A Platz; W C Willett; M J Stampfer; N Majeed; G A Colditz; F E Speizer; S E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-04       Impact factor: 4.254

6.  IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells.

Authors:  S Kansra; D Z Ewton; J Wang; E Friedman
Journal:  Int J Cancer       Date:  2000-08-01       Impact factor: 7.396

7.  IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells.

Authors:  A Di Popolo; A Memoli; A Apicella; C Tuccillo; A di Palma; P Ricchi; A M Acquaviva; R Zarrilli
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

8.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.

Authors:  R Kaaks; P Toniolo; A Akhmedkhanov; A Lukanova; C Biessy; H Dechaud; S Rinaldi; A Zeleniuch-Jacquotte; R E Shore; E Riboli
Journal:  J Natl Cancer Inst       Date:  2000-10-04       Impact factor: 13.506

9.  Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer.

Authors:  F el Atiq; F Garrouste; M Remacle-Bonnet; B Sastre; G Pommier
Journal:  Int J Cancer       Date:  1994-05-15       Impact factor: 7.396

10.  Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.

Authors:  K Szepeshazi; A V Schally; K Groot; P Armatis; G Halmos; F Herbert; B Szende; J L Varga; M Zarandi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  35 in total

1.  IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis.

Authors:  Astrid C Baege; Gary L Disbrow; Richard Schlegel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 2.  Role of insulin-like growth factor-1R system in colorectal carcinogenesis.

Authors:  Erin A Donovan; Shivaani Kummar
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-31       Impact factor: 6.312

Review 3.  Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions.

Authors:  Jeffrey A Meyerhardt
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

4.  Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer.

Authors:  A M M Haydon; R J Macinnis; D R English; H Morris; G G Giles
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 5.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge.

Authors:  Rajaraman Durai; Wenxuan Yang; Sharmila Gupta; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2005-01-14       Impact factor: 2.571

6.  Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.

Authors:  Charles S Fuchs; Richard M Goldberg; Daniel J Sargent; Jeffrey A Meyerhardt; Brian M Wolpin; Erin M Green; Henry C Pitot; Michael Pollak
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

7.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

8.  A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.

Authors:  Young-Ah Suh; Jai-Hyun Kim; Myung A Sung; Hye-Jin Boo; Hye Jeong Yun; Sun-Hye Lee; Hyo-Jong Lee; Hye-Young Min; Young-Ger Suh; Kyu-Won Kim; Ho-Young Lee
Journal:  Cancer Lett       Date:  2013-01-21       Impact factor: 8.679

9.  Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.

Authors:  Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Thomas E Rohan; JoAnn E Manson; Barbara V Howard; Judith Wylie-Rosett; Garnet L Anderson; Gloria Y F Ho; Robert C Kaplan; Jixin Li; Xiaonan Xue; Tiffany G Harris; Robert D Burk; Howard D Strickler
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

10.  Analysis of circulating insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) in tobacco smokers and non-smokers.

Authors:  R M Palmer; R F Wilson; P Y Coward; D A Scott
Journal:  Tob Induc Dis       Date:  2002-06-15       Impact factor: 2.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.